regulatory strategy Japan-arkiv - Biosector Ltd.

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Two executives in a golden-yellow meeting room lean over a large sheet of paper spread across the table. They are animatedly pointing and gesturing, immersed in discussion, as if the printed spreadsheet in front of them holds the key to their success in Japan’s pharma market.

by Stefan Sandström

September 19, 2025

Essential Gateways to Japan’s Pharma Ecosystem

An A3 Executive Reference (2 pages) Japan rewards programs that are sequenced, evidenced, and locally socialized. […]

0

by Stefan Sandström

BioPartner UK and Biosector: UK–Japan Life Sciences Bridge

Navigating Japan’s life sciences sector successfully hinges on more than just excellent science or a meticulously […]

0